Bolero 2 trial

Jan 10, 2013 In the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2), a randomized phase III study of 724 postmenopausal women with hormone. The BOLERO-2 trial evaluated the oral mammalian target of rapamycin inhibitor, everolimus (EVE), in combination with the steroidal aromatase inhibitor. Dec 7, 2011 In this phase 3, randomized trial, we compared everolimus and exemestane versus Oral Everolimus-2 (BOLERO-2) study reported here.

Mar 10, 2014 Background In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit. Sep 12, 2013 New analyses of the BOLERO-2 trial, presented at the 2013 Breast Cancer Symposium, held September 7-9 in San Francisco, California.

Sep 24, 2014 Researchers assessed one of the secondary endpoints, overall survival (OS), in the BOLERO-2 trial, which evaluated patients with hormone.

Characterization of response to everolimus in BOLERO-2: a

The BOLERO-2 trial (NCT00863655) evaluated the oral mammalian target of BOLERO-2 demonstrated that the median PFS more than doubled with EVE +. Jun 28, 2013 Sarat Chandarlapaty and colleagues report the identification of mutations in the ESR1 gene affecting the ligand-binding domain of the encoded.

A STUDY BASED ON THE BOLERO-2 TRIAL - Confex

Mar 28, 2014 This trial was looking at exemestane and everolimus (Afinitor) for breast receptor positive and has spread outside the breast (BOLERO 2). Jan 15, 2013 [3-5] In clinical trials, AIs provided longer time to progression compared In addition, results from the BOLERO-2 trial were recently published. The BOLERO-2 study is an international, multicenter, randomized, double-blind, PBO-controlled, phase III trial (ClinicalTrials. gov registration: NCT00863655).

Mar 25, 2014 Eagerly-awaited results from the BOLERO-2 trial looking at the mTOR inhibitor Afinitor (everolimus) plus the aromatase inhibitor Aromasin. Oct 21, 2014 3G-6 COST-EFFECTIVENESS ANALYSIS OF METASTATIC BREAST CANCER TREATMENTS: A STUDY BASED ON THE BOLERO-2 TRIAL.

Feb 19, 2014 New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression - free survival (PFS) than.

A trial of exemestane with or without everolimus for breast

Relapse while on adjuvant ET but after the first 2 years, or mainly clinical trials and not necessarily clinical prac ce. BOLERO-2: Everolimus + Exemestane. One proposed mechanism for resistance is aberration of the PI3K/AKT/mTOR pathway which has recently been supported by the BOLERO-2 trial results where. The BOLERO-2 trial is a potentially practice-changing study and offers new hope for our patients. — Jame Abraham, MD, Editor. A preplanned interim anal-.